Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
99 studies found for:    weill | "RNA Virus Infections"
Show Display Options
Rank Status Study
1 Terminated Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I
Condition: Hepatitis C
Interventions: Biological: Interleukin 2;   Drug: Ribavirin;   Biological: Pegylated Interferon Alpha;   Biological: Inteleukin-2;   Drug: Ribavirin + Pegylated interferon-alpha
2 Unknown  The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
Conditions: Hepatic Encephalopathy;   Hepatitis C;   Liver Cirrhosis
Intervention: Drug: Rifaximin (drug)
3 Completed
Has Results
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
Conditions: HIV-Associated Lipodystrophy Syndrome;   Insulin Resistance;   HIV Infections;   Metabolic Syndrome X;   Body Weight Changes
Interventions: Drug: Rosiglitazone;   Drug: Recombinant human growth hormone + rosiglitazone
4 Enrolling by invitation Hepatitis C Treatment in Underserved Populations
Conditions: Chronic Hepatitis C;   Illicit Drug Use
Intervention: Other: Collaborative, multidisciplinary, integrated care
5 Terminated Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin
Conditions: Anemia;   Neutropenia;   Hepatitis C Virus;   HIV Infections
Intervention: Drug: erythropoietin, GCSF
6 Completed The Shang Ring: A Novel Male Circumcision Device for HIV Prevention
Conditions: Male Circumcision;   HIV Prevention;   HIV Infections
Intervention: Device: Shang Ring circumcision
7 Completed
Has Results
Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
Condition: Hepatitis C
Interventions: Drug: Telaprevir;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
8 Completed Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects
Condition: Chronic Hepatitis C
Intervention: Drug: Ribavirin, PEG-Intron
9 Terminated
Has Results
Armodafinil for Patients Starting Hepatitis C Virus Treatment
Condition: Hepatitis C
Interventions: Drug: Armodafinil;   Drug: Sugar Pill
10 Completed Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
Condition: HIV Infections
Interventions: Biological: ALVAC HIV vaccine (vCP1452);   Drug: Interleukin-2
11 Completed A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs
Condition: HIV Infections
Interventions: Drug: Indinavir sulfate;   Drug: Nevirapine;   Drug: Lamivudine;   Drug: Stavudine;   Drug: Didanosine
12 Completed Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
Condition: HIV Infection
Interventions: Drug: Maraviroc;   Drug: Emtricitabine;   Drug: Tenofovir disoproxil fumarate;   Other: Maraviroc placebo;   Other: Emtricitabine placebo;   Other: Tenofovir disoproxil fumarate placebo
13 Completed
Has Results
HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV
Condition: HIV Infections
Interventions: Drug: Efavirenz;   Drug: Emtricitabine/Tenofovir disoproxil fumarate
14 Terminated
Has Results
Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Conditions: Thrombocytopenia;   Hepatitis C;   HIV Infections
Intervention: Drug: Anti-D
15 Completed Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
Condition: HIV Infections
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Drug: Aldesleukin
16 Unknown  An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
Condition: Parainfluenza
Interventions: Drug: DAS181-F02 Dry Powder in Bulk;   Drug: DAS181-F02 Nebulized Formulation Inhaled Dose
17 Active, not recruiting A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
Condition: Parainfluenza
Interventions: Drug: DAS181 dry powder, formulation F02;   Drug: Lactose Placebo
18 Recruiting IMPAACT P1107: Effects of Cord Blood Transplantation With CCR5Δ32 Donor Cells on HIV Persistence
Condition: HIV Infection
Intervention:
19 Completed
Has Results
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
Condition: HIV-1 and Hepatitis C Co-Infection
Interventions: Drug: pioglitazone;   Drug: peginterferon;   Drug: ribavirin
20 Active, not recruiting Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Condition: Liver Disease
Interventions: Drug: sofosbuvir/ledipasvir;   Drug: sofosbuvir;   Drug: Ribavirin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.